Confluent HTM monolayers, allowed to establish a stable morphology over a 7-day period,
35 were serum-starved for 24 hours. Cells were serum starved to synchronize RhoA-mediated signaling pathways that regulate cell spreading and actin polymerization.
36 Cells were then trypsin-treated and resuspended in serum-free DMEM containing 25 μg/mL cycloheximide. Both cycloheximide, which inhibits de novo protein synthesis, and serum-free medium were used in the assay to prevent unwanted signaling events mediated by serum matrix proteins and serum factors that would make it difficult to interpret the assay results. Among the serum components that would be problematic are the matrix proteins fibronectin, vitronectin,
37 38 39 and lysophosphatidic acid.
36 These serum components are known to activate integrin-specific signaling events. Cells were plated onto glass coverslips coated with poly-
l-lysine (PL), fibronectin, vitronectin, type I collagen, type IV collagen, vascular cell adhesion molecule (VCAM)-1 or the III
7–10, III
12–14 or IIICS domains of fibronectin. All substrates except the fibronectin domains were at 20 nM in PBS. The fibronectin fragments were at 100 nM in PBS. Cells were allowed to spread for 3 hours and then fixed with −20°C methanol for 15 minutes or 4%
p-formaldehyde plus 0.18% Triton X-100 for 30 minutes. Human fibronectin and the III
7–10, III
12–14, and IIICS domains were produced as described.
40 41 Human vitronectin and human VCAM-1 were provided by Deane Mosher (University of Wisconsin, Madison, WI). Human type I collagen and bovine type IV collagen were obtained from Southern Biotechnology Associates, Inc. (Birmingham, AL), and Chemicon International, Inc. (Temecula, CA), respectively. In experiments with soluble antibodies, suspended cells were incubated for 10 minutes in the presence of 10 μg/mL mAb GAL-13 against β-galactosidase (Sigma-Aldrich), 10 μg/mL mAb B3B11 against β1 integrin (Chemicon International, Inc.), 8 μg/mL mAb AP-5 against β3 integrin (The Blood Center of Southeastern Wisconsin; Milwaukee, WI), or 6 μg/mL mAb JBS2 against α2β1 integrin (Chemicon International, Inc.) and then plated, in the presence of the same soluble antibodies, on PL-coated coverslips. In other assays, cells were spread, in the absence or presence of soluble mAb AP-5 against β3 integrin, on coverslips coated with either the various antibodies or matrix substrates just described. In experiments with antibodies used as coating substrates, glass coverslips were precoated with 1:100 unconjugated goat anti-mouse IgG (Jackson ImmunoResearch, Inc, West Grove, PA). In experiments examining the effects of DEX pretreatment on CLAN formation, cells were spread in the absence or presence of 500 nM DEX.